CytomX

$8.94
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.29 (-3.20%) As of 1:43 PM EDT today
-$0.29 (-3.20%) Today

Why Robinhood?

You can buy or sell CytomX and other stocks, options, ETFs, and crypto commission-free!

About CTMX

CytomX Therapeutics, Inc. engages in the development of antibody therapeutics for the treatment of cancer based on its Probody therapeutic technology platform. Its pipeline includes immunotherapies, probody drug conjugates, T cell engaging bispecifics, and other multiple programs. Read More The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.

Employees
137
Headquarters
South San Francisco, California
Founded
2010
Market Cap
419.13M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
310.40K
High Today
$9.26
Low Today
$8.89
Open Price
$9.15
Volume
147.74K
52 Week High
$24.34
52 Week Low
$8.78

Collections

CTMX Earnings

-$0.74
-$0.48
-$0.23
$0.03
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Q3 2019
Estimated
Actual
Expected Nov 5, After Hours
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.